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Abstract 
3 
It is important for sarcoma patients to receive the correct dose of Mesna as an adjuvant with 
Ifosfamide to reduce the risk of haemorrhagic cystitis. This paper describes a study conducted to 
evaluate the physicochemical stability of Mesna for injection formulation over 14 days. 
Mesna samples (n=4, 20mg/mL) were incubated in glass vials at 37+0.5ºC. Mesna 
concentrations were determined by LC-MS/MS, and NMR was used to detect degradation 
products. Evaporative losses and pH were also monitored.  
Our results differed from those published in existing literature. Both LC-MS/MS and NMR 
indicated that Mesna was unstable. The mean percentage decrease in Mesna concentration was 
40% by day 14 of the analysis. The presence of Mesna’s dimer Dimesna was detected on day 0 
and its concentration increased over time. Dimesna was the only byproduct identified 
To conclude, both LC-MS/MS and NMR analyses confirmed the instability of Mesna and its 
conversion into Dimesna. 
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Introduction 
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Mesna, sodium 2-sulfanylethanesulfonate, is a thiol-containing compound commonly used as an 
adjuvant, orally or intravenously with Ifosfamide and Cyclophosphamide, to reduce the risk of 
haemorrhagic cystitis caused by the by-product acrolein.(1–8) 
Previous studies have confirmed that Mesna does not react with Ifosfamide, obstruct the tumour 
response to treatment or enter the cancer cells at all. This could be due to its hydrophilic 
properties, which prevents it from passing through the lipid biological membranes.(1,8–10) 
Mesna detoxifies acrolein via a similar mechanism to that of the naturally occurring thiol 
compound glutathione (found in the body in very low quantities).(1,11–13) 
Upon entering the bloodstream, Mesna is oxidised to form its less active dimer Dimesna (dithio-
bis-mercaptoethanesulphonate).(1,2) Similarly to Mesna, Dimesna is a hydrophilic compound 
which does not transfer across the lipid biological membrane through passive diffusion.(14) 
Upon reaching the kidneys, Dimesna is reduced back to Mesna and rapidly excreted due to its 
high solubility in water.(1,6) Previous studies have demonstrated that Mesna should be 
administered “continuously” to patients to prevent haemorrhagic cystitis.(15–22)   
One of the regimens for the treatment of metastatic soft tissue sarcoma (MSTS) is the 
combination of Mesna with Ifosfamide (1:1) as a continuous intravenous infusion via elastomeric 
pumps for 14 days.(23) To ensure patients safety and reduce haemorrhagic cystitis, it is 
important to demonstrate that Mesna is stable and the desired dose is maintained for the duration 
of the infusion.  
Previous work carried out by the authors of this paper on the stability of Ifosfamide and Mesna 
in elastomeric pumps using HPLC-PDA, showed an apparent increase in Mesna concentration 
5 
over the duration of analysis (24,25) though other investigators (using HPLC-UV) have indicated 
that Mesna was either stable or had a clinically insignificant decrease in its concentration over 
time. (26–28) However, other authors have suggested that HPLC with UV detection is not a 
suitable technique for the analysis of Mesna/Dimesna. James et al (1986) described the detection 
and quantification of Mesna and Dimesna in the patients’ urine using high performance liquid 
chromatography coupled to electrochemical detection.(29) Verschraagen et al also used 
electrochemical detection to quantify Mesna and Dimesna concentrations in patients’ plasma and 
urine.(30) Yet many subsequent studies have used HPLC-UV to investigate the stability of 
Mesna under various conditions.(26–28,31) 
Despite the widespread clinical use of Mesna, few studies have investigated its stability using a 
suitable analytical method (other than HPLC-UV) and none considered the possibility of 
Dimesna forming in the infusion. Therefore, the aim of this study was to evaluate the 
physicochemical stability of Mesna and quantify any Dimesna forming at 37ºC for average adult 
doses; using a validated Liquid Chromatography-Mass Spectrometry (LC-MS/MS) method and 
Nuclear Magnetic Resonance Spectroscopy (NMR). 
 
 
 
 
Materials and Methods 
6 
a. Materials  
Mesna for injection formulation (400mg/4mL) was obtained from Baxter Healthcare Ltd (West 
Berkshire, UK). Dimesna 100mg was purchased from Lorne Laboratories (Houston, USA). 
Water for Injection was purchased from HameIn Pharmaceuticals (Gloucester, UK).  HPLC 
grade water and acetonitrile were obtained from Fisher Scientific (Loughborough, UK). 
Analytical grade Mesna, sodium bicarbonate, 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium 
salt, ethylenediaminetetraacetic acid (EDTA) and ethyl-4-hydroxybenzoate were purchased from 
Sigma Aldrich (Poole, UK).  
b. Sample preparation 
Mesna for injection samples (n=3, 20 mg/mL) were prepared by diluting Mesna for injection 
ampoules from two different batches (samples 1& 2 from batch 1A314, sample 3 from batch 
2A051) with water for injection (Table 1). Samples were incubated in glass vials at 37+0.5ºC. 
For LC-MS/MS analysis, each sample was diluted further (0.0005 mg/mL) in triplicate using 
water for injection and 1000 µL of the 0.001 mg/mL internal standard solution. A separate 
Mesna sample (sample 4, batch 2A051) was prepared for the NMR analysis, deuterium oxide (10 
% v/v, for 1 ml total volume) was added during the sample preparation and a trace amount of 3-
(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt was used as a reference. 
c. Instrumentation 
The LC-MS/MS analysis was performed using a Thermo system consisting of an Accela 
autosampler (Thermo Scientific, UK), Triple Quadrupole TSQ quantum access mass 
spectrometer (Thermo Electron Corporation, UK), an Accela gradient pump (Thermo Scientific, 
UK) and a reversed-phase C8 ultrasphere column (4.6 mm x 250 mm, 5 µm; Beckman Coulter 
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6UE0255). Ethyl-4-hydroxybenzoate was used as an internal standard. The column temperature 
was maintained at 37°C and the autosampler temperature was held at 20°C. The mobile phase 
was acetonitrile (Solvent A) and 1% aqueous ammonium bicarbonate (Solvent B). The flow rate 
was 1000 µL/min and the solvent composition was 50:50 for 3 minutes before Solvent A was 
increased linearly to 100% at 4.5 min. Electrospray ionisation (ESI) was used in negative ion 
mode with spray voltage of 4000 V and capillary temperature of 250°C. Detection was by 
selected reaction monitoring (SRM) with the ion transitions as shown in Table 2.  
For NMR analysis, analytical grade Mesna and Dimesna (20 mg/mL) were initially run on 
a Brüker Avance III 400 MHz FT-NMR spectrometer using a gradient enhanced 1D NOESY 
water suppression pulse sequence to generate 1D proton spectra. TopSpin 3.0 pl4 and Icon NMR 
4.5.4 build 51 control and processing software were used to acquire and process the data. 
Subsequently, Mesna for injection (20 mg/mL) was run on a Brüker Avance III 600 MHz FT-
NMR spectrometer using the same experiment to obtain 1D proton spectra. The lower resolution 
spectrometer was equipped with a 5 mm broadband multinuclear probehead (PABBO BB-1H/D 
Z-GRD, Bruker BioSpin GmbH) whilst the higher resolution spectrometer was equipped with a 5 
mm triple resonance inverse probehead (PATXI 1H/D-13C/15N Z-GRD, Bruker BioSpin 
GmbH). 
d. LC-MS/MS method development and validation 
Fresh samples of Mesna (1 mg/mL) were prepared each day and used to prepare 7 calibration 
standards that were analysed immediately. Dimesna stock solution (1 mg/mL) was prepared and 
stored at -80ºC to prepare 7 calibration standards daily. Furthermore, QC samples of Mesna were 
spiked with either HCl or EDTA to attempt to stabilise Mesna in solution. The LC-MS/MS 
method was tested for accuracy, precision, linearity, limit of detection (LOD) and limit of 
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quantification (LOQ) following both the International Conference on Harmonisation (ICH) and 
the Food and Drugs Administration (FDA) guidelines.(32,33)   
Precision: Intraday precision, was determined by analysing 3 concentrations of Mesna in 
triplicate.  Mean, standard deviation and the coefficient of variation were calculated.  
Accuracy: Accuracy was determined by analysing 3 concentrations of Mesna in triplicate and 
comparing their measured concentrations to the known values.(34)   
Calibration Curves: the instrument was calibrated in the range 0-1000 PPB. 
Limits of Detection and Quantification:  Limit of detection (LOD) and quantification (LOQ) 
determination were based on the standard deviation of the response and the slope approach.(32) 
Three replicates of Mesna were analysed and their standard deviation was calculated together 
with the slope of their calibration curves.(34,35) 
e. Chemical and physical stability tests 
The chemical stability of Mesna was assessed by LC-MS/MS, NMR, evaporative loss and pH 
analysis. The physical stability was also assessed by visual examination under normal 
fluorescent light for the presence of particulates and colour changes. 
f. Samples and Data Analysis 
Each vial was subsampled on days 0, 1, 4, 7, 8, 9, 11 and 14 of the experiment. Each subsample 
was diluted further using water for injection and ethyl-4-hydroxybenzoate (internal standard) 
producing 3 solutions that were analysed in triplicate. A further Mesna sample was analysed on a 
Bruker Avance III 600 MHz FT-NMR spectrometer. The water peak position, suppressed in the 
final 1D proton experiments, was determined each time using a single pulse experiment 
involving a 360deg pulse. The receiver gain was determined for the first experiment in the series 
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(at T0) and was kept constant throughout the study. Thus only O1P (the irradiation offset, set to 
the water peak position) was optimised each time (around 4.70ppm). The sweep width was 10.0 
ppm (6.0 KHz) centered on the water peak. The spectra were recorded as the average of 16 scans 
of 65K complex data points. The data were processed using a single exponential windowing 
function (lb = 0.2 Hz) and the baseline was automatically adjusted in each spectrum using a 
polynomial (degree 5) function. 
 
Results and Discussion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
•  LC-MS/MS Method Validation 
 
Validation results for both compounds were within the limits specified by regulatory guidelines 
(Table 3).(33) Analysis of QC samples of Mesna was difficult due to the fast formation of 
Dimesna during sample preparation. Attempts to stabilise Mesna/Dimesna by the addition of 
EDTA and acid (HCl) were unsuccessful and affected the chromatography resulting in poor peak 
shapes and so were discontinued.  
•  Chemical and Physical Stability of Mesna using LC-MS/MS and NMR 
 
The results obtained from LC-MS/MS analysis showed that Mesna was unstable over the 
duration of analysis. Dimesna was detected on day 0 and its concentration increased over time at 
37°C. Mesna concentration dropped over the duration of the experiment (Figure 1). The mean 
percentage of loss in Mesna concentration for the three samples was 40% by day 7 and remained 
constant until day 14; statistical analysis confirmed the significance of the trends shown in 
Figure 1 (ANOVA, p<0.001). 
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Mesna’s dimer was either present initially in the vial or started forming immediately upon 
dilution, by the formation of a disulphide bridge between two Mesna monomers.(1) It was 
previously reported by Verchraagen et al that the stability of Mesna in urine samples was 
improved by increasing ethylenediaminetetraacetic acid (EDTA) concentration in the 
samples.(30) Verchraagen et al results demonstrated that the half-life of Mesna increased by up 
to 6 times in urine samples containing EDTA or hydrochloric acid. EDTA is added by the 
manufacturer to the pre-formulation vials to stablise Mesna. 
The rate of auto-oxidation reaction and the amount of Dimesna formed was different for samples 
made from different batches of Mesna as shown in Figure 2. Samples 1 and 2 were prepared 
from the same batch and had a higher percentage of loss in Mesna concentration and Dimesna 
formation over time (64% and 49% respectively), while, sample 3 had only 34% loss in Mesna 
concentration by day 14. The manufacturer’s tolerated concentration range for EDTA in the 
Mesna for injection formulation is between 0.2 - 0.3 mg/mL. This variation in EDTA 
concentration will affect the rate of dimer formation explaining the different rate of degradation 
between batches.  
The NMR analysis of sample 4 corroborated the results obtained by LC-MS/MS. The NMR 
integral regions for Mesna and Dimesna were 3.37-3.32, 3.16-3.08 and 3.26-3.19, 3.07-3.02 ppm 
respectively. Dimesna was present in the solution from day 0 and increased in concentration over 
time as shown in Figure 3 and Figure 4. Quantitative analysis of the 1H NMR data has also 
confirmed the trend of Dimesna formation. In particular, it demonstrated a similar trend to that of 
Mesna sample 3 (both samples 3 and 4 are from the same batch). Mesna concentration decreased 
rapidly up to day 7 (Figure 5 and Figure 6). Dimesna was the sole reaction product detected by 
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NMR. This finding was in agreement with the findings of James et al in a study that investigated 
the metabolism of Mesna in plasma.(36) 
The pH of samples 1 - 3 was determined and found to be in the range 7.9-6.8 (average readings 
were 7.9 on day 0, 7.5 on day 4, 6.8 on day 14). This drop in pH would be a consequence of the 
auto-oxidation of Mesna mechanism of reaction, which releases protons during Dimesna 
formation (Figure 7). Evaporative losses were insignificant, below 1% over the duration of the 
experiment. 
The physical stability results showed that the Mesna solutions remained clear and colourless 
until day 4. White solid particles were observed by day 7 in all three samples. Mesna is highly 
soluble in water (>100 mg/mL) and therefore it is unlikely that the particles are Mesna crystals. 
The drop in the pH of the solution may promote Dimesna precipitation. 
Expert Commentary 
In conclusion, a reliable and specific LC-MS/MS method was developed for the detection and 
quantification of Mesna and Dimesna. The Triple Quadrupole Mass Spectrometer is a far more 
selective detector than the PDA used previously in existing published methods.  Both LC-
MS/MS and NMR analyses confirmed the instability of Mesna and its conversion into Dimesna. 
The mean percentage decrease in Mesna concentration was 41% at 37°C by day 14. Dimesna 
was found to be the only degradation product formed and the extent of conversion varied among 
the Mesna samples possibly due to batch variations in EDTA concentration. 
Overall, the findings of this experiment were different to those of previous studies (26,27,37) and 
showed that Mesna was not stable, forming Dimesna. The use of Dimesna was tested in 
combination with Cisplatin and Paclitaxel or Docetaxel during clinical trials phase I and II to 
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treat patients suffering ovarian, lung and head and neck cancer.(38,39) Recently, Dimesna was 
also used for clinical trials phase III as a continuous intravenous infusion along with Taxane and 
Cisplatin chemotherapy for the treatment of non-small lung cancer, however it is not a licensed 
drug.(40) 
Clinically, Dimesna possesses similar therapeutic properties to Mesna when administered 
intravenously as Mesna dimerises immediately upon entering the bloodstream.(1,2) According to 
our results, treatments given to patients via elastomeric pumps will not only contain Mesna, but 
also Dimesna. However, the presence of Dimesna, and particularly the drop in pH associated 
with its formation may destabilise other drugs in the formulation causing sub therapeutic dosing 
and affecting treatment efficacy.  Furthermore, the physical instability of the Mesna formulation, 
and the formation of particles by day 7 will affect the total Mesna dosage given to patients, and if 
this effect is significant, worsen the effects of haemorrhagic cystitis or delay the end of infusion 
by blocking the pumps’ filter. Further studies would be needed to establish whether this has any 
clinical significance. 
It is important to test the combination of Ifosfamide and other drugs administered with Mesna in 
order to determine synergistic effects that may affect the stability of the formulation and possible 
effects on treatment outcomes.  
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Five-year View  
This paper showcased the stability profile of a common regimen, Ifosfamide/Mesna used for 
MSTS patients. It is interesting to note that all previous stability studies published on Mesna 
showed that it was chemically stable. The findings of this manuscript were different to those of 
previous studies as Mesna was shown to be not stable, forming Dimesna. This was not evident in 
the previous studies mainly because of the specificity/selectivity of the used analytical procedure 
- HPLC with UV detection - is not a suitable technique for the analysis of Mesna/Dimesna. 
Results of this paper indicate the clear need to investigate the stability of anticancer therapies, 
under similar conditions to those used in practice, using a suitable and specific analytical 
method. It is anticipated that more stability tests should be performed on current chemotherapy 
regimens duplicating exact standard clinical practice conditions i.e. concentration of the drugs, 
type of delivery container, exact diluent, temperature and other incubation parameters. Each of 
these parameters might alter the stability of the drug of interest and lead to sub-dosing the 
patients, introduce additional side effects depending on the toxicity of the degradation products 
and/or affect the chemical compatibility within the formulation.  
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Key Issues  
• Results detailed in this manuscript describe an example where ensuring the 
specificity/selectivity of an analytical procedure is important to avoid producing 
misleading results. HPLC with UV detection was shown to be a not suitable technique for 
the analysis of Mesna/Dimesna. 
• The conversion of Mesna into Dimesna has not been reported before and implies that  
MTST patients prescribed with IV Ifosfamide/Mesna, over 7 days using elastomeric 
pumps are also receiving Dimesna in their infusion..  
•  Temperature is a key parameter to consider for the stability of anticancer therapies. 
Regulating the temperature surrounding the elastomeric pump, depending on the 
chemotherapeutic formulation and its stability profile / rate of degradation, may improve 
the stability of the therapy. 
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